Skip to main content Skip to search Skip to main navigation
News: Europa

EU GMP Guide: Chapter 4, Annex 11 and New Annex 22

The EC has published the long-awaited revised and new documents of the EU GMP Guide for consultation: Chapter 4 Documentation, Annex 11 Computerised Systems and the new Annex 22 Artificial Intelligence. Stakeholder consultations are open until 7 October on the EC website.

Revision of Chapter 4 – Documentation

The updated Chapter 4 emphasises the critical role of documentation in GMP and supports the use of digital, hybrid, and emerging technologies. Risk-based data governance is now a core element to ensure document accuracy, integrity, availability, and legibility across all formats. It also clarifies requirements for managing electronic records, signatures, and data integrity, aligning with the ongoing revision of Annex 11.

Revision of Annex 11 – Computerised Systems

The updated Annex 11 reinforces lifecycle management of computerised systems, requiring comprehensive application of Quality Risk Management. It strengthens requirements for system specifications, supplier oversight, data integrity, audit trails, electronic signatures, and security.

New Annex 22 – Artificial Intelligence

Annex 22 sets out requirements for the use of AI and machine learning in the manufacture of active substances and medicinal products. It covers model selection, training, validation, and performance monitoring. Key areas include intended use, data quality, performance metrics, change control, and human oversight.


Source:

EC: Public Health/Consultations/ Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: Europe

EDQM: New working party on 3D-printed medicinal products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
News: Artificial Intelligence

Annex 22: Results of the EMA Workshop

On 30 June, the EMA’s Annex 22 Working Group discussed the future scope of the annex with AI experts and representatives of the pharmaceutical industry (as previously reported).
Read more
News: Artificial Intelligence

EMA Workshop Regarding Annex 22 "Artifical Intelligence"

The current draft of Annex 22, "Artificial Intelligence", proposes excluding generative AI and large language models (LLMs), as well as probabilistic, dynamic and adaptive AI models, from critical GMP applications. Numerous comments submitted during the public consultation challenged this approach. Instead, the aim should be to support innovation and encourage investment by the pharmaceutical industry.
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Previous
Next